エピソード

  • NTLA Today - Jul 15: Stock Barely Budges

    NTLA Today - Jul 15: Stock Barely Budges
    2026/07/15
    Hey there! It’s Joey here, your friendly investor buddy. Let’s chat about how Intellia, or NTLA, moved today. Spoiler alert: it was a pretty chill day, with the stock barely budging at all.

    So, NTLA was up just a smidge, like 0.23%. Not exactly a wild ride, right? Volume was super low, too. I mean, 528,000 shares traded when the average is over 6 million? Yeah, that’s a slow day for sure.

    Now, why did it move like a sloth today? Honestly, not a lot of buzz in the air. Some chatter about other biotech stocks took the spotlight instead. Plus, there's some bearish sentiment floating around, especially from folks who think Intellia might be overvalued and lacking in commercial potential. That one stung a bit, right? But, hey, stocks do their own thing sometimes, and it doesn’t always make sense.

    Looking ahead, there’s some interesting stuff going on in the biotech space, but nothing super specific for Intellia that’s causing a stir right now. Just the usual noise about gene-editing stocks being hot topics.

    Anyway, just wanted to keep you in the loop about NTLA today. Remember, this is just for your info and entertainment, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • NTLA Today - Jul 14: Market Cues Keep It Steady

    NTLA Today - Jul 14: Market Cues Keep It Steady
    2026/07/14
    Hey, what’s up? It’s Joey here, your friendly neighborhood investor, breaking down what went down today with Intellia, or NTLA for short. It was a bit of a chill day, just a slight green move, up about three-quarters of a percent. Not exactly a wild ride, but hey, better than a red day, right?

    So, here’s the scoop. NTLA barely moved today, which is kinda surprising given all the buzz in the market. The broader market was a bit shaky, with S&P 500 futures slipping lower ahead of some big news from the Fed next week. You know how it is—everyone’s on edge, and it seems like folks were more focused on that than anything specific to Intellia.

    Now, why did Intellia stay steady? Well, it looks like people are just kinda waiting it out. There’s a lot of chatter about gene-editing stocks right now, and Intellia is definitely on the radar. Some articles even called it one of the best gene-editing stocks for 2026. But honestly, today felt more like a holding pattern. Investors might be playing it safe, not wanting to make any big moves with the Fed news lurking around the corner. Plus, with all this AI hype and semiconductor chatter, NTLA kinda got lost in the shuffle.

    Oh, and speaking of the future, there’s some buzz about upcoming earnings reports in the tech sector that could shake things up. That might bring some attention back to stocks like NTLA. Just something to keep in mind as we move forward.

    So, to wrap it up, Intellia had a quiet day, just hanging in there as the market figures out its next move. Remember, this is just for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • NTLA Today - Jul 13: Intellia Takes a Hit

    NTLA Today - Jul 13: Intellia Takes a Hit
    2026/07/13
    Hey there! It’s Joey, your friendly investor here, breaking down what went down today. We’re talking about Intellia, or NTLA, and it was a rough day—down about 6.6%. Ouch!

    So, what happened? NTLA got smoked today, dropping a good chunk of change. There was a lot of trading, but it didn’t help much. People were hitting that sell button fast, and the stock just couldn’t catch a break.

    Now, why the drop? Well, it seems like there wasn’t any specific news that triggered this sell-off. Sometimes stocks just move on vibes or the overall market mood, you know? The buzz around the market was kinda mixed today, with some stocks like RKLB and others getting attention while NTLA just sat there. It’s like when you’re at a party, and everyone’s dancing, but you’re stuck in the corner sipping your drink. Nobody really knows why Intellia took such a hit today, but it definitely stung for folks holding the bag.

    On a more positive note, NTLA has actually surged about 38% over the past month. So, while today was a bummer, there's been some serious momentum building recently. It's wild how fast things can change in this game.

    To wrap it up, today was a tough day for Intellia. But with that recent rally, it’s clear there’s still some interest in the stock. Just remember, investing can be a rollercoaster, and it’s not always smooth sailing. So, keep your head up and do your homework. This is just for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • NTLA Today - Jul 12: Stung by Phase 3 Data

    NTLA Today - Jul 12: Stung by Phase 3 Data
    2026/07/12
    Hey there! It’s Joey, your friendly neighborhood investor here to break down what went down with Intellia, or NTLA. Today was a rough day for the stock, and it got smoked, dropping about 8%. Ouch, right?

    So, here’s the scoop. Intellia started the day kinda strong but then took a nosedive after some news about their Phase 3 trial results for Lonvo-z. Even though the data was positive, it didn’t seem to sit well with investors. They hit that sell button pretty quick. I mean, when the market is feeling jittery, any little thing can make folks skittish.

    Now, why did this happen? Well, the buzz around the stock was that even with the promising results, there were some big questions lingering about the future. They’ve got plans to launch in 2027, but that feels like forever away, right? Plus, there was chatter about Cathie Wood and her trades, which usually stirs the pot. But today, it was all about those Phase 3 results and what it means for the launch timeline. Investors are probably worried about the timeline and what it means for Intellia’s bottom line.

    On a side note, Intellia has actually surged about 38% over the last month, so this drop is kinda surprising. It's like a reality check after a wild ride.

    One thing worth keeping an eye on is how Intellia’s management responds to this dip. They might have some plans up their sleeve to reassure investors, but we'll see how that plays out.

    So, to wrap it up, yeah, today was a tough day for NTLA. It’s always a rollercoaster in the stock market, and this one definitely had its downs today. Just remember, I’m here for the info and fun chat, not to dish out financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • NTLA Today - Jul 11: Positive Data, But Down Big

    NTLA Today - Jul 11: Positive Data, But Down Big
    2026/07/11
    Hey there! It’s Joey here, your friendly longtime investor, breaking down what went down with Intellia, or NTLA for short. Today was a rough one for the stock, which got smoked, dropping almost 8%. Ouch!

    So, here’s the scoop. Intellia had some positive news about their Phase 3 Lonvo Z data that got folks buzzing. You’d think that would send the stock skyrocketing, right? But nope, instead it took a nosedive. People were probably expecting a bigger pop from the news, and when it didn’t deliver, they hit the sell button fast. The stock's been on a wild ride recently, up about 38% over the last month. But today? Total reversal.

    Why the sudden drop? Well, there’s chatter about how even with the success of the Lonvo Z data, some investors are feeling cautious. Maybe they’re worried about the launch plans for 2027 or just think the stock’s been hyped too much too fast. It’s like when you get a new phone and everyone’s raving about it, but then you find out it has a few glitches. That one stung.

    On the bright side, Wedbush is still on board with Intellia, even raising their price target to $17. So, there’s some hope in the mix. But with all this volatility, who knows what’s next?

    Just a quick heads-up: the earnings report from Q1 shows a narrower loss, so that’s a little glimmer of positivity in the midst of all this.

    Anyway, that's the lowdown on NTLA today. Just remember, this is for your info and entertainment, not financial advice. Keep it chill, and catch you later!
    続きを読む 一部表示
    1 分
  • NTLA Today - Jul 10: Intellia's Wild Ride

    NTLA Today - Jul 10: Intellia's Wild Ride
    2026/07/10
    Hey there! It’s Joey, your friendly neighborhood investor, here to break down what just went down with Intellia, or NTLA for short. Today was a rough one – the stock got smoked, down about 7% by the end of the day. Ouch!

    So, what happened? Well, Intellia had a wild ride lately, with a big surge just yesterday. People were super hyped because they were about to get the first-ever Phase 3 readout for their gene-editing therapy. But today? That excitement took a nosedive. The volume was pretty high, though, so clearly, a lot of folks were trading it, but the mood shifted fast.

    Now, why did it drop? A couple of reasons. Some analysts are saying the stock looks pricey when you consider sales versus returns. Like, yeah, it might seem rich on paper, but the actual performance isn’t matching the hype. Plus, there’s chatter that it could be around 37% below what it should be worth based on its gene-editing prospects. That kind of uncertainty can make investors hit the sell button real quick.

    And here’s something worth keeping an eye on: Wedbush just raised their price target for NTLA to $17. That’s a little glimmer of hope in an otherwise cloudy day.

    So, to wrap it up: NTLA had a rough day after a big high yesterday. Analysts are a bit skeptical about its valuation, which definitely rattled some nerves. Just remember, I’m here to share info and keep it fun, but this isn’t financial advice. Always do your own homework! Catch you later!
    続きを読む 一部表示
    1 分
  • NTLA Today - Jul 09: Mixed Signals in the Market

    NTLA Today - Jul 09: Mixed Signals in the Market
    2026/07/09
    Hey there! It’s Joey, your friendly neighborhood investor, and I’m breaking down what happened today with Intellia, or NTLA for short. So, today was a bit of a red day for them, down about 1% at $16.66. Yeah, that one stung a little.

    Now, here’s the scoop. NTLA started off strong, even jumping in premarket trading thanks to some positive news about late-stage trial data for their gene-editing therapy. People were hyped, thinking it was a great moment to jump in. But as the day went on, the excitement fizzled out. The stock saw a good amount of volume but ended up just barely moving by the close. It seems like folks were a bit hesitant, hitting the sell button instead of piling on the buys.

    So, why the sudden mood shift? Well, some articles pointed out that while Intellia is looking good in terms of potential sales, it’s not really delivering strong returns right now. Plus, there’s chatter that the stock might be around 37% below what it should be worth based on its gene-editing hopes. That could be making investors think twice. It’s like a classic case of “what have you done for me lately?” People are looking for those solid returns, and if they’re not seeing them, they might get skittish.

    On the horizon, you should know that there’s been a lot of buzz about NTLA's upcoming earnings report. That could definitely shake things up, for better or worse.

    So, in a nutshell, NTLA had a mixed day. They started strong but ended up feeling the heat from some cautious investors. As always, just keep in mind this is all for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • NTLA Today - Jul 09: Stock Takes a Small Dip

    NTLA Today - Jul 09: Stock Takes a Small Dip
    2026/07/09
    Hey there! It's Joey, your go-to guy for stock talk. I’ve been investing for years, and today we’re checking out Intellia, or NTLA. It was a bit of a rough day – the stock dipped about 1% today.

    So, what happened? Well, NTLA opened the day strong but then kind of faded away. It got smoked for a little while, and by the end, it was sitting at $16.66. Not the best look, right? Trading volume was way below average, too, which usually means people aren’t super excited about it right now.

    Now, why did this happen? There’s some chatter out there about how NTLA looks a bit pricey based on its sales but isn’t pulling in the returns investors want. Some folks are saying it could be overvalued by around 37% considering all the hype about gene editing. Yeah, that one stung a bit for some investors. Even with some positive vibes from late-stage trial data, it seems like the market's not fully buying into the hype just yet.

    On the horizon, there’s talk about NTLA's gene-editing therapy. It’s still in the spotlight, and some retail investors are saying now's the time to jump in before it’s too late. So, there’s definitely some action brewing, but it’s a mixed bag.

    That’s the scoop for today! Remember, I’m just here to share the info, not to give you financial advice. Keep it real, and catch you later!
    続きを読む 一部表示
    1 分